Morphine for Dyspnea in Pulmonary Fibrosis | NCT04497831 | Trialant

Morphine for Dyspnea in Pulmonary Fibrosis | NCT04497831 | Trialant

Arms/Interventions Module

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
The primary end point is a reduction of breathlessness intensity by ≥20 mm at 100 mm visual analogue scale (VAS) after nebulization, during daily, normal activities	The primary end point is a reduction of breathlessness intensity by ≥20 mm at 100 mm visual analogue scale (VAS) after nebulization, during daily, normal activities	Breathlessness during daily, normal activities will be measured with VAS 1 hour before nebulization and 4 hours after

Secondary Outcomes

Measure	Description	Time Frame
Secondary end point	Secondary end points are: reduction of breathlessness intensity by ≥20 mm at 100 mm visual analogue scale (VAS) following six minute walking test (6MWT) performed after nebulization improvement of 6MWT distance by ≥30 m reduction of cough severity by ≥17 mm at 100 mm visual analogue scale (VAS) after nebulization, during normal activities reduction of chest pain severity by ≥19 mm at 100 mm visual analogue scale (VAS) after nebulization, during normal activities reduction of cough severity by ≥17 mm at 100 mm visual analogue scale (VAS) during six minute walking test (6MWT) performed after nebulization reduction of chest pain severity by ≥19 mm at 100 mm visual analogue scale (VAS) following six minute walking test (6MWT) performed after nebulization

Eligibility Module

Condition Browse Module